Stock Track | GENSCRIPT BIO Soars 5.08% Intraday on Underlying Sales Growth and European mRNA Expansion

Stock Track

Mar 17

GENSCRIPT BIO's stock price surged 5.08% during intraday trading on Tuesday, marking a significant upward movement for the biotechnology company.

The movement appears linked to the market's assessment of the company's recently reported full-year 2025 financial results and its strategic expansion. While the company swung to a reported net loss of US$532.83 million from a prior-year profit, this was primarily due to the absence of a large one-time unrealised gain from deconsolidation recorded in 2024. Investors may be focusing on the underlying operational performance, which saw sales rise to US$959.53 million.

Further optimism is likely driven by the company's ongoing investment in its high-growth platforms, particularly its mRNA capabilities. The recent opening of its Delft mRNA manufacturing facility in the Netherlands embeds the company in a major European life sciences hub. Analyst projections included in related coverage suggest significant future revenue and earnings growth by 2028, alongside a fair value estimate representing substantial upside potential from current price levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1145814400"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145814400\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145814400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145814400","market":"nz","top_or_hot":-1,"title":"Stock Track | GENSCRIPT BIO Soars 5.08% Intraday on Underlying Sales Growth and European mRNA Expansion","media":"Stock Track","content":"<p>GENSCRIPT BIO's stock price surged 5.08% during intraday trading on Tuesday, marking a significant upward movement for the biotechnology company.</p><p>The movement appears linked to the market's assessment of the company's recently reported full-year 2025 financial results and its strategic expansion. While the company swung to a reported net loss of US$532.83 million from a prior-year profit, this was primarily due to the absence of a large one-time unrealised gain from deconsolidation recorded in 2024. Investors may be focusing on the underlying operational performance, which saw sales rise to US$959.53 million.</p><p>Further optimism is likely driven by the company's ongoing investment in its high-growth platforms, particularly its mRNA capabilities. The recent opening of its Delft mRNA manufacturing facility in the Netherlands embeds the company in a major European life sciences hub. Analyst projections included in related coverage suggest significant future revenue and earnings growth by 2028, alongside a fair value estimate representing substantial upside potential from current price levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENSCRIPT BIO Soars 5.08% Intraday on Underlying Sales Growth and European mRNA Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENSCRIPT BIO Soars 5.08% Intraday on Underlying Sales Growth and European mRNA Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-17 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO's stock price surged 5.08% during intraday trading on Tuesday, marking a significant upward movement for the biotechnology company.</p><p>The movement appears linked to the market's assessment of the company's recently reported full-year 2025 financial results and its strategic expansion. While the company swung to a reported net loss of US$532.83 million from a prior-year profit, this was primarily due to the absence of a large one-time unrealised gain from deconsolidation recorded in 2024. Investors may be focusing on the underlying operational performance, which saw sales rise to US$959.53 million.</p><p>Further optimism is likely driven by the company's ongoing investment in its high-growth platforms, particularly its mRNA capabilities. The recent opening of its Delft mRNA manufacturing facility in the Netherlands embeds the company in a major European life sciences hub. Analyst projections included in related coverage suggest significant future revenue and earnings growth by 2028, alongside a fair value estimate representing substantial upside potential from current price levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1145814400","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145814400","pubTimestamp":1773713207,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GENSCRIPT BIO's stock price surged 5.08% during intraday trading on Tuesday, marking a significant upward movement for the biotechnology company.The movement appears linked to the market's assessment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"个股追踪|金斯瑞生物盘中大涨5.08%，因基础销售增长和欧洲mRNA扩张","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GENSCRIPT BIO's stock price surged 5.08% during intraday trading on Tuesday, marking a significant upward movement for the biotechnology company.The movement appears linked to the market's assessment of the company's recently reported full-year 2025 financial results and its strategic expansion. While the company swung to a reported net loss of US$532.83 million from a prior-year profit, this was primarily due to the absence of a large one-time unrealised gain from deconsolidation recorded in 2024. Investors may be focusing on the underlying operational performance, which saw sales rise to US$959.53 million.Further optimism is likely driven by the company's ongoing investment in its high-growth platforms, particularly its mRNA capabilities. The recent opening of its Delft mRNA manufacturing facility in the Netherlands embeds the company in a major European life sciences hub. Analyst projections included in related coverage suggest significant future revenue and earnings growth by 2028, alongside a fair value estimate representing substantial upside potential from current price levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}